| 000 | 01800 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515113332.0 | ||
| 264 | 0 | _c20080722 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a0160-2446 | ||
| 024 | 7 |
_a10.1097/FJC.0b013e318163a90f _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSacristán, Daniel | |
| 245 | 0 | 0 |
_aEffects of coronary prestenting platelet inhibition on coronary poststenting inflammation. _h[electronic resource] |
| 260 |
_bJournal of cardiovascular pharmacology _cMar 2008 |
||
| 300 |
_a286-92 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInflammation _xetiology |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyocardial Infarction _xtherapy |
| 650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aPlatelet Glycoprotein GPIIb-IIIa Complex |
| 650 | 0 | 4 |
_aStents _xadverse effects |
| 650 | 0 | 4 |
_aTiclopidine _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTirofiban |
| 650 | 0 | 4 |
_aTyrosine _xadministration & dosage |
| 650 | 0 | 4 |
_aalpha 1-Antitrypsin _xdrug effects |
| 700 | 1 | _aLópez-Farré, Antonio José | |
| 700 | 1 | _aZamorano-León, José Javier | |
| 700 | 1 | _aAzcona, Luis | |
| 700 | 1 | _aFernández-Ortiz, Antonio | |
| 700 | 1 | _aRomero, José | |
| 700 | 1 | _aFarré, Jerónimo | |
| 700 | 1 | _aMacaya, Carlos | |
| 773 | 0 |
_tJournal of cardiovascular pharmacology _gvol. 51 _gno. 3 _gp. 286-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/FJC.0b013e318163a90f _zAvailable from publisher's website |
| 999 |
_c17857558 _d17857558 |
||